MedTrace Logo

Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery

NCT02291432 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-11-01

Study results available
· View outcomes & findings →

Summary

To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.

Conditions

  • Urinary Incontinence
  • Stress
  • Urination Disorders
  • Urologic Diseases
  • Lower Urinary Tract Symptoms
  • Urological Manifestations

Interventions

BIOLOGICAL

autologous muscle-derived cells (AMDC)

Cell treatment

Sponsors & Collaborators

  • Cook MyoSite

    lead INDUSTRY

Principal Investigators

  • Kenneth Peters, MD · Beaumont Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-19
Primary Completion
2019-06-28
Completion
2019-06-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02291432 on ClinicalTrials.gov